Juan Pablo Frias

40PUBLICATIONS
73CO-AUTHORS
EndocrinologyCancer therapy (excl. chemotherapy and radiation therapy)Nutrigenomics and personalised nutritionApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Jul 31, 2026
Is Hypercortisolism Treatable? Which Patients Should Be Treated and How-A Practical Guide for Clinicians.

|Aug 05, 2025
Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial.

Manu V Chakravarthy, Michael A Elliott, Luis Acosta

|Jul 10, 2025
What is the 'real-world' experience with fixed-ratio combination therapy (insulin + GLP-1 receptor agonist) in routine clinical practice? Take-home messages for clinicians regarding key outcomes.

Juan Pablo Frias

|Feb 11, 2025
Novel pharmacotherapies for weight loss: Understanding the role of incretins to enable weight loss and improved health outcomes.

Thomas Forst, Christophe De Block, Stefano Del Prato

|Feb 05, 2025
Effect of iGlarLixi on continuous glucose monitoring-measured time in range in insulin-naive adults with suboptimally controlled type 2 diabetes.

Juan P Frías, Alexandria Ratzki-Leewing, Terry Dex

|Jul 29, 2024
The role of incretin receptor agonists in the treatment of obesity.

Thomas Forst, Christophe De Block, Stefano Del Prato

Pageof 7

Frequent Collaborators

8 joint publications

Julio Rosenstock

6 joint publications

Vanita R Aroda

6 joint publications

Stefano Del Prato

5 joint publications

Serge Jabbour